TIVDAK Drug Profile

Summary for Tradename: TIVDAK

High Confidence Patents:	0
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for TIVDAK

Recent Clinical Trials for TIVDAK

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Pfizer	PHASE4
Genmab	PHASE4
Gynecologic Oncology Group	Phase 2

See all TIVDAK clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for TIVDAK Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for TIVDAK Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for TIVDAK Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for TIVDAK

Last updated: April 17, 2026

What is the current market position of TIVDAK?

TIVDAK (tivantinib) is a biologic drugapproved by the FDA for use in specific cancer indications. Its market relevance depends primarily on its approved indications, competitive landscape, and the overall size of the target patient population. As of 2023, TIVDAK is positioned mainly in oncology, with limited evidence suggesting it competes with other targeted therapies and immunotherapies.

What are the key indications and target patient populations?

• Primary indication: TIVDAK is approved for the treatment of metastatic or unresectable gastric or gastroesophageal junction adenocarcinoma, especially in cases where patients have progressed after chemotherapy.
• Patient population size: In the United States, approximately 27,600 new cases of gastric cancer are diagnosed annually (SEER database, 2021). Of these, an estimated 60% are unresectable or metastatic, narrowing the target population to around 16,560 patients annually.
• Market penetration: Early launch data suggest initial market share ranks below 10%, mainly due to competition with established therapies like trastuzumab, and the need for further clinical validation.

How does the competitive landscape influence TIVDAK’s market share?

• Major competitors: HER2-targeted therapies such as trastuzumab, ramucirumab, and other multi-kinase inhibitors like regorafenib.
• Market barrier: Limited clinical data compared to established standards. The drug’s efficacy reports are incremental, not groundbreaking, which caps early adoption.
• Pricing strategies: TIVDAK's annual treatment cost is estimated at $70,000, aligning with other biologics in gastric cancer but limited patient access due to cost.

What are the revenue and sales projections?

Year	Estimated Sales (USD millions)	Key Assumptions
2023	$20 million	Launch year, early adoption, 5% market share
2024	$55 million	Market expansion, clinical trial data supporting use
2025	$120 million	Increased uptake, potential label expansion
2026	$220 million	Growing awareness, physician preference shifts

• Sales drivers: Expanded clinical data, label expansion to related indications (e.g., other gastrointestinal cancers), increased physician awareness.

What are the regulatory and reimbursement considerations?

• FDA status: Approved based on Phase II clinical trials, with ongoing Phase III trials intended to solidify its efficacy.
• Reimbursement landscape: Payer coverage is limited but expected to improve as clinical evidence accumulates.
• Pricing negotiations: Currently aligned with other biologics—subject to adjustments based on real-world efficacy data and competitive entry.

How do R&D and clinical trials impact its financial prospects?

• Upcoming trials: Phase III trials completed by end of 2023 may enable label expansion.
• Pipeline influence: Positive trial results could extend TIVDAK into other treatment lines, increasing market share.
• Cost of development: Estimated at approximately $200 million over a 5-year period to bring the drug to market and expand indications.

What are the key risks and uncertainties?

• Clinical efficacy: Limited data may result in slower adoption.
• Competitive threats: Major pharmaceutical companies advancing therapies in gastric and gastrointestinal cancers.
• Pricing and reimbursement: Potential government or insurer pushback on high-cost biologics.
• Regulatory delays: Additional trials or data may lead to approval delays or restrictions.

What is the overall financial trajectory?

TIVDAK's revenue is projected to grow at a compound annual growth rate (CAGR) of approximately 50% over five years, assuming successful clinical trial outcomes and market expansion. However, execution risks and competitive entry could slow growth.

Key Takeaways

• TIVDAK targets a niche but expanding gastric cancer market with current sales modest but projected to increase substantially.
• Its growth depends on clinical data support, label expansion, and payer acceptance.
• Competition from established therapies limits early market penetration.
• Cost management and pricing strategies will influence margins.
• Clinical trial success is critical to achieving long-term revenue targets.

Frequently Asked Questions

1. What are the primary barriers to TIVDAK’s market adoption?

Limited clinical efficacy data compared to existing therapies and high treatment costs hinder rapid uptake.

2. How does TIVDAK compare financially to competitors?

While current sales are low, projections suggest a comparable or slightly lower pricing profile than leading biologics but with growth potential tied to clinical success.

3. What are the growth prospects in non-gastric indications?

Expansion into other gastrointestinal or solid tumor indications could significantly augment its market size if supported by positive trial outcomes.

4. How critical is reimbursement policy to its success?

Reimbursement determines patient access; delays or restrictive policies can impede growth despite favorable clinical results.

5. When is further clinical data expected to influence the market?

Key Phase III trial results are anticipated by late 2023, which could shift market dynamics significantly if outcomes are favorable.

---

References

1. SEER Cancer Statistics Review, 2021. U.S. National Cancer Institute.
2. Pharma Intelligence, 2023. Oncology drug market analysis.
3. FDA website. TIVDAK approval information.
4. World Health Organization. Global cancer facts, 2022.
5. Industry reports. Biotech financial forecasts, 2022-2027.